Kathmandu: Rainbow Trade Concern, one of Nepal’s leading pharmaceutical importers, has reported a steady 6 percent growth in business for calendar year 2025.
The company recorded total sales of Rs 2.59 billion in 2025, up from Rs 2.44 billion in 2024. This continues its consistent upward trend:
2025: Rs 2.59 billion
2024: Rs 2.44 billion
2023: Rs 1.94 billion
2022: Rs 1.78 billion
2021: Rs 1.63 billion
Established in 1993 and fully owned by businessman Suresh Kumar Agarwal, Rainbow Trade is the exclusive distributor in Nepal for India’s Intas Pharmaceuticals. It imports a wide range of medicines, especially for epilepsy, diabetes, hypertension, and other chronic conditions.
The company supplies more than 100 wholesale distributors across Nepal.
Recent credit ratings show Rainbow Trade has arranged rating facilities worth Rs 89.4 million (Rs 14.9 million long-term and Rs 74.5 million short-term). Notably, 42 percent of its total business now comes from its top 10 customers (up from 40 percent in 2024), reflecting strong and growing relationships with key partners.
With steady year-on-year growth over the past five years, Rainbow Trade Concern continues to strengthen its position as a reliable lifeline for essential medicines in the Nepali market.
Comment Here